LFVN vs. PHVS, AVBP, COGT, OCS, BCYC, DNA, IMNM, AVDL, CVAC, and CDMO
Should you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), Bicycle Therapeutics (BCYC), Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry.
LifeVantage vs.
Pharvaris (NASDAQ:PHVS) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
Pharvaris has a beta of -3.08, suggesting that its stock price is 408% less volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Pharvaris presently has a consensus target price of $40.50, suggesting a potential upside of 145.60%. LifeVantage has a consensus target price of $30.50, suggesting a potential upside of 82.74%. Given Pharvaris' higher probable upside, equities analysts clearly believe Pharvaris is more favorable than LifeVantage.
LifeVantage has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
In the previous week, LifeVantage had 1 more articles in the media than Pharvaris. MarketBeat recorded 1 mentions for LifeVantage and 0 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.90 beat LifeVantage's score of 1.67 indicating that Pharvaris is being referred to more favorably in the media.
35.3% of LifeVantage shares are held by institutional investors. 11.8% of Pharvaris shares are held by company insiders. Comparatively, 20.7% of LifeVantage shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
LifeVantage received 187 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 77.97% of users gave LifeVantage an outperform vote while only 66.67% of users gave Pharvaris an outperform vote.
LifeVantage has a net margin of 3.46% compared to Pharvaris' net margin of 0.00%. LifeVantage's return on equity of 34.29% beat Pharvaris' return on equity.
Summary
LifeVantage beats Pharvaris on 13 of the 16 factors compared between the two stocks.
Get LifeVantage News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LifeVantage Competitors List
Related Companies and Tools
This page (NASDAQ:LFVN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LFVN Stock Alerts